A retrospective analysis revealed that chemotherapy combination with trastuzumab reduced cancer relapse in 5 of 18 (27%) patients with HER2+ BCSC-enriched tumors compared to the patients who received only chemotherapy (p = 0.019). This evidence concerns the gene ERBB2 and cancer.